Clearside Biomedical Inc (NASDAQ:CLSD) gapped down prior to trading on Friday . The stock had previously closed at $0.86, but opened at $0.78. Clearside Biomedical shares last traded at $0.72, with a volume of 21,950 shares.
Several equities research analysts have weighed in on CLSD shares. JMP Securities reissued an “outperform” rating and issued a $3.00 price target (down previously from $4.00) on shares of Clearside Biomedical in a report on Thursday. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Laidlaw downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Zacks Investment Research raised Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.50 price target for the company in a report on Monday, August 12th. Finally, Wedbush reissued a “buy” rating and issued a $4.00 price target on shares of Clearside Biomedical in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $3.64.
The company has a debt-to-equity ratio of 0.69, a current ratio of 3.47 and a quick ratio of 3.47. The stock has a market cap of $27.38 million, a price-to-earnings ratio of -0.26 and a beta of -0.88. The stock has a fifty day moving average of $1.13 and a 200 day moving average of $1.24.
Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. As a group, equities analysts expect that Clearside Biomedical Inc will post -0.98 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in CLSD. Jane Street Group LLC acquired a new position in shares of Clearside Biomedical during the second quarter worth about $98,000. Paloma Partners Management Co acquired a new position in shares of Clearside Biomedical during the second quarter worth about $122,000. Vanguard Group Inc. lifted its stake in shares of Clearside Biomedical by 66.9% during the second quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock worth $899,000 after purchasing an additional 370,690 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Clearside Biomedical during the second quarter worth about $95,000. Finally, Parallel Advisors LLC acquired a new position in shares of Clearside Biomedical during the first quarter worth about $87,000. 11.56% of the stock is owned by hedge funds and other institutional investors.
About Clearside Biomedical (NASDAQ:CLSD)
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.